Aristotle University Of Thessaloniki (AUTH)
Μελέτη της επίδραση της έξωνεφρικής κάθαρσης σε υποπληθυσμούς των Τ- λεμφοκυττάρων διαβητικών και μη διαβητικών ασθενών με χρόνια νεφρική νόσο τελικού σταδίου και συσχέτιση με αρτηριοσκληρυντικές αγγειακές αλλοιώσεις
Abstract
dc:descriptionChronic kidney disease (CKD) is assosiated with immune deficiency. Immune system alterations involve both innate and acquired immunity. Progressive loss of renal function and accumulation of uremic toxins lead to a preferential loss of lymphoid cells, while myeloid cells remain almost untouched. Regarding T cell immunity CKD leads to a decrease in number and function of several T lymphocyte subsets, especially affecting naïve and memory subpopulations. These alterations resemble those observed during ageing or chronic inflammatory conditions. More specifically, there is a preferential loss of CD28 expression in CKD, which increases susceptibility to activation induced apoptosis in both CD4 and CD8 T cells. This phenomenon has been associated with chronic inflammation that accompanies CKD, however, it may also be subsequent to subclinical CMV re-activation in these patients. Interestingly, CD28- T lymphocytes appear to be highly differenciated cells, and as recent evidence suggest, they play a significant role in chronic inflammatory conditions including atherosclerosis. As a consequence of aquired immune alterations, CKD patients are highly susceptible to infections and respond poorly to vaccination. Furthermore, they are at an increased risk of developing atherosclerotic cardiac disease. T lymphocyte alterations, such as a decrease in regulatory T cells and an increase in CD4CD28null T cells have long been recognised as contributing to accelerated atherosclerosis and cardiovascular disease; the main cause of death in the CKD population. Activated CD4 T lymphocytes, Natural Killer (NK) cells and macrophages are the basic components of the atheromatous plaque as originally shown in animal models of atherogenesis. In addition, during the last two decades CD4CD28null T cells were associated with acute coronary events and have been suggested as a biomarker and potential therapeutic target in CVD. Recent studies advocate that increased morbidity and mortality in chronic kidney disease patients may be a direct consquence of the chronic subclinical inflammatory state, which leads to alterations in both innate and acquired immunity. Data from recent studies compairing T cell alterations in pre-dialysis and dialysis state are scarce and conflicting. Some investigators have reported further alterations in patients immunological profile after initiation of dialysis, while others found no difference between pre dialysis and dialysis state. The present prospective longitudinal study aimed to investigate T cell alterations in ESRD patients in pre-dialysis state compaired to age and gender mached healthy volunteers. Additionally the effect of different dialysis methods (hemodialysis, peritoneal dialysis) was also assessed regarding T cell alterations. More specifically, CD4+, CD8+, CD4+CD28null and CD8+CD28null and CD4+CD25+ T-cells were analyzed using flow cytometry in 41 ESRD patients (21 males/ 20 females) at two different time points, i) at pre dialysis state (ESRD-T0) and ii) six months later (ESRD-T6), while being stable on hemodialysis (HD) or peritoneal dialysis (PD). Twenty age matched healthy volunteers served as controls. The results of the study showed a significant reduction in both the percentage and total number of T cells compared to controls (1382+605 vs 2311+419, p<0,001) while neutrophil number was not significantly affected [4659 (3757-6440) vs 3850 (3490-4193)]. This finding is in agreement with that of the majority of previously published studies. Another interesting finding of the study was that CKD patients had increasead percentage of CD4CD28null T cells (7.6+7.8 vs 3+2.3 p<0.001) as well as CD8CD28null T cells (46.4+20.5 vs 35.4+14.1, p= 0.029) compared to controls. As mentioned previously, loss of CD28 expression is a feature of highly differentiated T cells after repeated antigen stimulation and appears to be a marker of immunological aging. These exhausted T cells, despite the loss of their effector functions seem to retain some cytotoxic functions. More specificly, CD4CD28null T cells have been extensively studied in atherosclerotic cardiovascular disease. There are no published studies about the role of CD8CD28null T cells so far. In our study population, both CD4CD28null and CD8CD28null T cells seem to increase in parallel levels. In addition, a high percentage of both subpopulation in our CDK subjects correlated with CMV seropositivity (IgG CMV+). This finding suggests that loss of CD28 expression in CKD patients seems to be driven by a common stimulating factor, which could be the accumulation of uremic toxins or possibly CMV chronic re-activation. This phenomenon has been described in other conditions such as autoimmune diseases and CKD. Several previous studies have associated CMV seropositivity with a relative risk of CVD, although conclusions are still inconcistent.As a secondary outcome CD28null T cells correlated with intima media thickness of the carotid artery. Some of these findings are in agreement with previous studies that have described a positive correlation between CD4CD28null and IMT. However, there are no previous studies estimating the result of CD28 elimination on CD8 cells, namely the correlation between CD8CD28null T cells and IMT. Our results sugest a potential new role for CD8CD28null T cells in atherosclerotic CVD. Furthermore, another important finding of our study was that both total CD4 and Treg numbers were decreased compared to controls. It is well known that CKD affects almost all T cell subsets, but mostly naïve and memory T cells. Previous studies have reported a decrease in total lymphocytes, NK cells and Tregs along with the progression of GFR decline. Low levels of Tregs in CKD and dialysis populations have been proposed as potential risk factors for allograft rejection. A rather interesting and novel finding of the second phase of the study is that hemodialysis led to a significant further reduction in Treg cells while CD4CD28null cells increased. On the other hand, patients who started on peritoneal dialysis, retained a rather favorable immunological profile considering Tregs and CD4CD28null T cells. To the best of our knowledge, this is the first study to report a favorable outcome in immunological patient profile of peritoneal dialysis versus hemodialysis. These novel findings need to be investigated in larger study population groups, as they may be extremely important for patients awaiting kidney transplantation, while selecting dialysis method to start on. In terms of the immunological profile, peritoneal dialysis seems to have a favorable effect, as it retains Treg cell numbers and have a lower impact in CD4CD28null T cells than hemodialysis, resulting in a lower risk of cardiovascular complications. Nevertheless, these findings need to be confirmed in larger randomized studies. Finally, in an effort to assess the impact of diabetes mellitus on these immune alterations, diabetic CKD patients were also studied as a subpopulation, and their immunological profile was compared to that of CKD patients without diabetes mellitus. In patients with diabetes, both CD4CD28null and CD8CD28null cells were significantly increased before starting on dialysis compared to CKD patients without diabetes mellitus. Patients on hemodialysis showed a further increase in CD8CD28null T cells, while on the contrary, there was a decrease in CD4CD28null T cells in diabetic patients commencing on peritoneal dialysis. This finding suggests a possible benefit for the diabetic CKD patients that choose peritoneal dialysis in terms of cardiovascular complications. We believe that all these novel and extremely interesting results need to be confirmed in long term observational studies.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sampani, Erasmia
- Σαμπάνη, Ερασμία
Subjects
dc:subject × 22- Αιμοκάθαρση, Χρόνια νεφρική
- Συνεχής φορητή περιτοναϊκή κάθαρση (ΣΦΠΚ)
- Ανοσοποιητικό σύστημα
- CD4 Τ λεμφοκύτταρα
- Διαβήτης (σακχαρώδης)
- Αρτηριοσκλήρυνση
- Αρτηριοσκληρυντικές αλλοιώσεις
- Καρδιαγγειακή νόσος
- Chronic kidney failure
- Chronic hemodialysis
- Chronic ambulatory peritoneal dialysis (CAPD)
- Immune system
- CD4 T lymphocytes
- Diabetes mellitus
- Arteriosclerosis
- Cardiovascular disease
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Νεφρολογία
- Clinical Medicine
- Medical and Health Sciences
- Nephrology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51000